Neoprobe Corporation (NEOP) today announced that it has completed its
corporate name change to Navidea Biopharmaceuticals, Inc. (NYSE Amex:
NAVB). The Company will begin trading under the ticker symbol, NAVB, on
the NYSE Amex at market open today. The CUSIP number for NAVB common
stock has also been changed to 63937X103.
The Navidea name and logo represent the Company’s dedication to
“NAVigating IDEAs” that translate cutting edge innovation and precision
diagnostics technology into novel products to advance patient care.
Navidea’s website is expected to be launched in the coming days and may
be found at www.navidea.com.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals (NYSE Amex: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively
developing three radiopharmaceutical agent platforms – Lymphoseek®,
AZD4694 and RIGScanTM – to help identify the presence and
status of disease and enable better diagnostic accuracy, clinical
decision-making and ultimately patient care. Navidea’s strategy is to
deliver superior growth and shareholder return by bringing to market
novel radiopharmaceutical agents and advancing the Company’s pipeline
through selective acquisitions, global partnering and commercialization
efforts. For more information, please visit www.navidea.com.